ArticleBiochemistry and biophysics reports2026
A regenerative strategy for vital pulp therapy: Platelet-rich fibrin augments stem cell viability and pluripotency in bioactive cement environments.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vital pulp therapy (VPT) aims to preserve pulp vitality and stimulate regeneration of the dentin-pulp complex. Dental pulp stem cells (DPSCs) are clonogenic mesenchymal stem cells with high self-renewal and multipotent differentiation capacity. Bioactive cements such as mineral trioxide aggregate (MTA) and calcium-enriched mixture (CEM) are widely used as pulp-capping agents due to their biocompatibility. Platelet-rich fibrin (PRF), an autologous fibrin matrix rich in cytokines and growth factors, has been used to support tissue healing and regeneration. Methods: Human third-molar DPSCs were isolated and characterized, then cultured with MTA, CEM, and combinations of cement with PRF. Cell viability was assessed using the MTT assay, and expression of pluripotency markers (OCT4, SOX2, NANOG) was quantified by real-time PCR. Results: MTT assays showed that CEM alone significantly reduced DPSC viability compared to control, whereas MTA and MTA + PRF did not differ from control. Notably, co-treatment with PRF attenuated CEM's adverse effect. NANOG was significantly upregulated in the MTA and MTA + PRF groups relative to control, and SOX2 was significantly elevated in the MTA + PRF group. OCT4 remained unchanged across all conditions. Conclusion: The combination of MTA and PRF enhanced DPSC survival and upregulated pluripotency markers (NANOG, SOX2), supporting its potential application in regenerative VPT. In contrast, CEM alone had a detrimental effect on cell viability; however, this adverse effect was attenuated by PRF co-application. These findings suggest that MTA + PRF is a promising pulp-capping strategy for preserving DPSC function and promoting pulp regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.